View Filing Data

Exercise Price

Expiry Date

January 6, 2022*

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Sep. 30, 2016	Dec. 09, 2016	Mar. 31, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY
Entity Registrant Name	Stellar Biotechnologies, Inc.
Entity Central Index Key	0001540159
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float			$ 39,507,208
Trading Symbol	SBOT
Entity Common Stock, Shares Outstanding		10,136,258

Consolidated Balance Sheets - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Current assets:
Cash and cash equivalents	$ 7,416,904	$ 3,955,503
Accounts receivable	85,813	157,597
Short-term investments	3,988,794	5,015,171
Inventory	249,430	557,280
Prepaid expenses	358,714	181,068
Total current assets	12,099,655	9,866,619
Noncurrent assets:
Equity investment in joint venture	66,695	0
Property, plant and equipment, net	756,114	503,408
Deposits	15,340	15,900
Total noncurrent assets	838,149	519,308
Total Assets	12,937,804	10,385,927
Current liabilities:
Accounts payable and accrued liabilities	623,644	656,685
Deferred revenue	0	173,333
Warrant liability, current portion	0	1,550,630
Total Current Liabilities	623,644	2,380,648
Commitments (Note 8)
Shareholders' equity:
Common shares, unlimited common shares authorized, no par value, 10,136,258 and 7,984,758 issued and outstanding at September 30, 2016 and 2015, respectively	47,280,792	38,114,215
Accumulated share-based compensation	5,394,763	5,226,379
Accumulated deficit	(40,361,395)	(35,335,315)
Total Shareholders' Equity	12,314,160	8,005,279
Total Liabilities and Shareholders' Equity	$ 12,937,804	$ 10,385,927

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Sep. 30, 2015
Common shares, par value	$ 0	$ 0
Common shares, shares issued	10,136,258	7,984,758
Common shares, shares outstanding	10,136,258	7,984,758

Consolidated Statements of Operations - USD ($)	1 Months Ended	12 Months Ended
Consolidated Statements of Operations - USD ($)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Revenues:
Product sales	$ 32,786	$ 1,239,689	$ 563,689	$ 143,553
Contract services revenue	20,000	32,000	195,000	192,000
Grant revenue	0	0	0	36,579
Revenues	52,786	1,271,689	758,689	372,132
Expenses:
Costs of sales and contract services	11,636	818,566	580,824	469,149
Costs of aquaculture	22,063	309,262	259,423	254,531
Grant costs	0	0	0	36,579
Research and development	178,280	1,729,445	1,029,489	2,458,934
General and administrative	293,130	3,322,772	3,227,545	2,871,455
Total Expenses	505,109	6,180,045	5,097,281	6,090,648
Income (Loss) from Operations	(452,323)	(4,908,356)	(4,338,592)	(5,718,516)
Other Income (Loss)
Foreign exchange gain (loss)	(97,866)	76,800	(653,333)	(222,437)
Gain (loss) in fair value of warrant liability	1,680,040	(211,956)	2,131,062	(2,533,305)
Investment income	1,853	24,632	54,634	61,935
Other Income (Loss), Total	1,584,027	(110,524)	1,532,363	(2,693,807)
Income (Loss) Before Income Tax	1,131,704	(5,018,880)	(2,806,229)	(8,412,323)
Income tax expense	3,800	7,200	36,800	27,200
Net Income (Loss)	$ 1,127,904	$ (5,026,080)	$ (2,843,029)	$ (8,439,523)
Earnings (loss) per common share:
Basic	$ 0.14	$ (0.57)	$ (0.36)	$ (1.11)
Diluted	$ 0.13	$ (0.57)	$ (0.36)	$ (1.11)
Weighted average number of common shares outstanding:
Basic (in shares)	7,867,575	8,826,312	7,956,962	7,582,664
Diluted (in shares)	8,714,045	8,826,312	7,956,962	7,582,664

Consolidated Statements of Cash Flows - USD ($)	1 Months Ended	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Cash Flows Used In Operating Activities:
Net income (loss)	$ 1,127,904	$ (5,026,080)	$ (2,843,029)	$ (8,439,523)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	12,529	149,565	159,521	158,313
Share-based compensation	36,509	259,379	267,222	956,634
Foreign exchange (gain) loss	97,866	(76,800)	653,333	222,437
(Gain) loss in fair value of warrant liability	(1,680,040)	211,956	(2,131,062)	2,533,305
Loss on disposal of property, plant and equipment	0	0	0	3,670
Impairment loss	0	0	0	90,476
Changes in working capital items:
Accounts receivable	12,352	71,827	(113,917)	121,075
Deferred share issuance costs	0	0	0	60,656
Inventory	(34,891)	307,850	(522,389)	0
Prepaid expenses	490	(197,150)	(45,758)	(94,974)
Deposits	0	560	0	0
Accounts payable and accrued liabilities	58,922	(33,403)	77,018	106,224
Deferred revenue	71,667	(173,333)	86,666	15,000
Net cash used in operating activities	(296,692)	(4,505,629)	(4,412,395)	(4,266,707)
Cash Flows From Investing Activities:
Acquisition of property, plant and equipment	(13,477)	(402,271)	(274,589)	(279,065)
Proceeds on sale of property, plant and equipment	0	0	0	2,150
Purchase of short-term investments	(2,491)	(11,995,450)	(13,677)	(5,468,815)
Proceeds on sales and maturities of short-term investments	2,821	13,021,827	410,736	0
Contribution to joint venture	0	(66,695)	0	0
Net cash provided by (used in) investing activities	(13,147)	557,411	122,470	(5,745,730)
Cash Flows From Financing Activities:
Proceeds from issuance of common shares, net	0	6,277,500	0	6,613,675
Payments for share issuance costs	0	(332,764)	0	(134,578)
Proceeds from exercise of warrants and options	739,292	1,368,260	106,777	4,308,878
Net cash provided by financing activities	739,292	7,312,996	106,777	10,787,975
Effect of exchange rate changes on cash and cash equivalents	(84,083)	96,623	(629,808)	(212,338)
Net change in cash and cash equivalents	345,370	3,461,401	(4,812,956)	563,200
Cash and cash equivalents - beginning of year	8,423,089	3,955,503	8,768,459	7,859,889
Cash and cash equivalents - end of year	8,768,459	7,416,904	3,955,503	8,423,089
Cash (demand deposits)	5,895,229	972,412	3,955,503	5,474,155
Cash equivalents	2,873,230	6,444,492	0	2,948,934
Cash and cash equivalents	$ 8,768,459	$ 7,416,904	$ 3,955,503	$ 8,423,089

Consolidated Statements of Changes in Equity - USD ($)	Total	Common Shares [Member]	Shares Subscribed [Member]	Accumulated Share-Based Compensation [Member]	Accumulated Deficit [Member]
Balance at Aug. 31, 2013	$ (2,195,999)	$ 13,180,677	$ 5,155,674	$ 4,648,317	$ (25,180,667)
Balance (in shares) at Aug. 31, 2013		5,794,616
Issuance of common shares	7,000,000	$ 12,000,000	(5,000,000)	0	0
Issuance of common shares (in shares)		1,142,857
Share issuance costs including fair value of broker units	(520,903)	$ (907,801)	0	386,898	0
Proceeds from exercise of warrants	3,764,460	$ 3,920,134	(155,674)	0	0
Proceeds from exercise of warrants (in shares)		593,730
Transfer to common shares on exercise of warrants	6,591,546	$ 6,591,546	0	0	0
Issuance of performance shares	0	$ 422,728	0	(422,728)	0
Issuance of performance shares (in shares)		151,515
Proceeds from exercise of options	544,418	$ 544,418	0	0	0
Proceeds from exercise of options (in shares)		144,167
Transfer to common shares on exercise of options	0	$ 489,136	0	(489,136)	0
Share-based compensation	956,634	0	0	956,634	0
Net loss	(8,439,523)	0	0	0	(8,439,523)
Balance at Aug. 31, 2014	7,700,633	$ 36,240,838	0	5,079,985	(33,620,190)
Balance (in shares) at Aug. 31, 2014		7,826,885
Proceeds from exercise of warrants	727,804	$ 727,804	0	0	0
Proceeds from exercise of warrants (in shares)		110,100
Transfer to common shares on exercise of warrants	860,397	$ 890,214	0	(29,817)	0
Proceeds from exercise of options	11,488	$ 11,488	0	0	0
Proceeds from exercise of options (in shares)		5,000
Transfer to common shares on exercise of options	0	$ 13,533	0	(13,533)	0
Share-based compensation	36,509	0	0	36,509	0
Net loss	1,127,904	0	0	0	1,127,904
Balance at Sep. 30, 2014	10,464,735	$ 37,883,877	0	5,073,144	(32,492,286)
Balance (in shares) at Sep. 30, 2014		7,941,985
Proceeds from exercise of warrants	12,609	$ 12,609	0	0	0
Proceeds from exercise of warrants (in shares)		4,020
Transfer to common shares on exercise of warrants	9,574	$ 10,000	0	(426)	0
Proceeds from exercise of options	94,168	$ 94,168	0	0	0
Proceeds from exercise of options (in shares)		38,753
Transfer to common shares on exercise of options	0	$ 113,561	0	(113,561)	0
Share-based compensation	267,222	0	0	267,222	0
Net loss	(2,843,029)	0	0	0	(2,843,029)
Balance at Sep. 30, 2015	8,005,279	$ 38,114,215	0	5,226,379	(35,335,315)
Balance (in shares) at Sep. 30, 2015		7,984,758
Issuance of common shares	6,750,000	$ 6,750,000	0	0	0
Issuance of common shares (in shares)		1,687,500
Share issuance costs	(805,264)	$ (805,264)	0	0	0
Proceeds from exercise of warrants	1,368,260	$ 1,368,260	0	0	0
Proceeds from exercise of warrants (in shares)		464,000
Transfer to common shares on exercise of warrants	1,762,586	$ 1,853,581	0	(90,995)	0
Share-based compensation	259,379	0	0	259,379	0
Net loss	(5,026,080)	0	0	0	(5,026,080)
Balance at Sep. 30, 2016	$ 12,314,160	$ 47,280,792	$ 0	$ 5,394,763	$ (40,361,395)
Balance (in shares) at Sep. 30, 2016		10,136,258

Nature of Operations

12 Months Ended

Sep. 30, 2016

Nature of Operations [Abstract]

Nature of Operations [Text Block]

Nature of Operations

Stellar Biotechnologies, Inc. (the “Company”) is organized under the laws of British Columbia, Canada. The Company’s common shares are listed on The Nasdaq Capital Market under the trading symbol “SBOT.” The Company’s common shares trade on The Nasdaq Capital Market in the United States under the symbol “SBOT” since November 5, 2015. From January 15, 2013 through November 4, 2015, the Company’s common shares were traded in the United States on the U.S. OTCQB Marketplace Exchange under the symbol “SBOTF.” From April 19, 2010 to April 8, 2016 the Company’s common shares were listed in Canada on the TSX Venture Exchange as a Tier 2 issue under the trading symbol “KLH.”

In April 2010, the Company changed its name from CAG Capital, Inc. to Stellar Biotechnologies, Inc. and completed a reverse merger transaction with Stellar Biotechnologies, Inc., a California corporation, which was founded in September 1999, and remains the Company’s wholly-owned subsidiary and principal operating entity. The Company’s executive offices are located at 332 E. Scott Street, Port Hueneme, California, 93041, USA, and its registered and records office is Royal Centre, 1055 West Georgia Street, Suite 1500, Vancouver, BC, V6E 4N7, Canada.

Nature of Operations

The Company’s business is the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (“KLH”). The Company markets and distributes its KLH products to biotechnology and pharmaceutical companies, academic institutions, and clinical research organizations in Europe, the United States, and Asia.

Management Plans

For the fiscal years 2016, 2015, and 2014, the Company reported net losses of approximately $5.0 million, $2.8 million, and $8.4 million, respectively. The most significant factor in the fluctuations in net income and losses relates to noncash changes in the fair value of warrant liability, which was a loss of $212,000, gain of $2.1 million, and loss of 2.5 million for the fiscal years 2016, 2015, and 2014, respectively. As of September 30, 2016, the Company had an accumulated deficit of approximately $40.4 million and working capital of approximately $11.5 million.

In the past, operations of the Company have primarily been funded by the issuance of common shares, exercise of warrants, grant revenues, contract services revenue and product sales. In July 2016, the Company closed a $6.75 million registered direct offering. Management believes the Company’s working capital is sufficient to support the Company’s current initiatives at the current level for at least 12 months. Management is also continuing the ongoing effort toward expanding the customer base for existing marketed products, and the Company may seek additional financing alternatives, including nondilutive financing through grants, collaboration and licensing arrangements, as well as additional equity financing and debt financing.

The accompanying consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities and commitments in the normal course of business.

Functional Currency

The consolidated financial statements of the Company are presented in U.S. dollars, which is the Company’s functional currency, unless otherwise stated.

Reverse Share Split

On September 2, 2015, the Company effected a share consolidation (reverse split) of the Company's common shares at a ratio of 1-for-10. As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share. The reverse split reduced the number of common shares outstanding from 79,847,550 to 7,984,758 after fractional share rounding. The number of warrants, broker units, and options were proportionately adjusted by the split ratio and the exercise prices correspondingly increased by the same split ratio. All historical shares and exercise prices are presented on a post-split basis in these condensed interim consolidated financial statements.

Basis of Presentation

12 Months Ended

Sep. 30, 2016

Basis of Presentation [Abstract]

Basis of Accounting [Text Block]

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of the Company and its wholly-owned subsidiary, Stellar Biotechnologies, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.

Change in Fiscal Year End

On June 3, 2014, the Board of Directors of the Company approved a change in the Company’s fiscal year end from August 31 to September 30 of each year. This change to the calendar quarter reporting cycle began September 1, 2014. As a result of the change, the Company had a one-month transition period from September 1, 2014 to September 30, 2014. Included in this report are the Company’s consolidated balance sheets as of September 30, 2016 and 2015; and the consolidated statements of operations, cash flows and changes in equity for the 12 months ended September 30, 2016 (“fiscal 2016”), September 30, 2015 (“fiscal 2015”), August 31, 2014 (“fiscal 2014”), and the one month ended September 30, 2014.

Significant Accounting Policies

12 Months Ended

Sep. 30, 2016

Significant Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These estimates include warrant liability, share-based compensation, intangible assets, valuation of accounts receivable, valuation of inventory, and income taxes. Actual outcomes could differ from these estimates. These consolidated financial statements include estimates, which by their nature are uncertain. The impacts of such estimates are pervasive throughout the consolidated financial statements, and may require accounting adjustments based on future periods if the revision affects both current and future periods. These estimates are based on historical experience, current and future economic conditions and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Cash and Cash Equivalents

Cash and cash equivalents consist of demand deposits with financial institutions and highly liquid investments which are readily convertible into cash with maturities of three months or less when purchased.

Investments

Investments at September 30, 2016 consisted of U.S. Treasury bills with original maturities between 13 and 52 weeks. They are classified as held-to-maturity and are reported at amortized cost, which approximates fair value. The Company regularly reviews these investments to determine whether any decline in fair value below the amortized cost basis has occurred that is other than temporary. If a decline in fair value has occurred that is determined to be other than temporary, the cost basis of the investment is written down to fair value. Investments at September 30, 2015 consisted of a mutual fund of short-term fixed, floating and variable rate debt securities with normal weighted average effective maturity of approximately 1 year or less. This mutual fund investment is reported at fair value using level 1 inputs.

Allowance for Doubtful Accounts Receivable

The Company assesses the collectability of its accounts receivable through a review of its current aging, as well as an analysis of its historical collection rate, general economic conditions and credit status of its customers. As of September 30, 2016 and 2015, all outstanding accounts receivable were deemed to be fully collectible, and therefore, no allowance for doubtful accounts was recorded.

Inventory

The Company records inventory at the lower of cost or market, with market not in excess of net realizable value. Raw materials are measured using FIFO (first-in first-out) cost. Work in process and finished goods are measured using average cost.

Property, Plant and Equipment

Property, plant and equipment are recorded at cost less accumulated depreciation and accumulated impairment losses, if any. Depreciation is recorded on the straight-line method over useful lives ranging from 1.5 to 15 years. Leasehold improvements are depreciated over the shorter of the useful life of the improvement or remaining term of lease. Maintenance and repairs are charged to operations as incurred.

Impairment of Long-Lived Assets

If indicators of impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, the amount of such impairment is measured by comparing the carrying value of the asset to the fair value of the asset and the Company records the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. See Note 7 for impairment of licensing rights.

Fair Value of Financial Instruments

The Company uses the fair value measurement framework for valuing financial assets and liabilities measured on a recurring basis in situations where other accounting pronouncements either permit or require fair value measurements. See Note 12 for fair value measurements.

Revenue Recognition

Product Sales

The Company recognizes product sales when KLH product is shipped (for which the risk is typically transferred upon delivery to the shipping carrier) and there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collectability is reasonably assured. The Company documents arrangements with customers with purchase orders and sales agreements.

Product sales include sales made under supply agreements with customers for a fixed price per gram of KLH products based on quantities ordered, including those produced from a customer’s designated limpet colonies. Supply agreements are typically on a non-exclusive basis except within that customer’s field of use.

Contract services revenue

The Company recognizes contract services revenue when contract services have been performed and reasonable assurance exists regarding measurement and collectability. An appropriate amount will be recognized as revenue in the period that the Company is assured of fulfilling the contract requirements. Amounts received in advance of performance of contract services are recorded as deferred revenue.

Contract services include services performed under collaboration agreements effective December 2013 through 2015 and monthly maintenance of limpet colonies designated to meet the needs of the customer through December 2014. The Company also had the right to use raw material produced from designated limpet colonies at no cost to the Company with prior written consent from the customer.

Grants

The Company has taken the income approach to recognizing grant revenue. The Company recognizes grant revenue when there is reasonable assurance that the Company will comply with the conditions attached, the benefits have been earned and it is reasonably assured of collection. An appropriate amount of earned revenue will be recognized as revenue in the period that the Company is assured of fulfilling the grant requirements.

Research and Development

Research and development expenses principally consist of personnel costs related to the Company’s research and development staff as well as depreciation of research and development assets. Research and development expenses also include costs incurred for laboratory supplies, reimbursable costs associated with government grants and collaborative agreements, third-party contract payments, consultants, facility and related overhead costs. Research and development costs are expensed as incurred.

Share-Based Compensation

The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees.

The fair value of share-based compensation is measured on the date of grant, using the Black-Scholes option valuation model and is recognized over the vesting period net of estimated forfeitures for employees or the service period for non-employees. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option.

Foreign Exchange

Items included in the financial statements of the Company’s subsidiary are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The functional currency of the parent and its subsidiary is the U.S. dollar.

Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.

Income Taxes

Income tax expense comprises current and deferred tax. Income tax is recognized in income or loss except to the extent that it relates to items recognized directly in equity. Current tax expense is the expected tax payable on taxable income for the year, using tax rates enacted or substantively enacted at year-end, adjusted for amendments to tax payable with regards to previous years.

Deferred tax is recorded using the liability method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Temporary differences are not provided for relating to goodwill not deductible for tax purposes. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the balance sheet date.

A deferred tax asset is recognized only to the extent that it is more likely than not that future taxable profits will be available against which the asset can be utilized. To the extent that the Company does not consider it more likely than not that a deferred tax asset will be recovered, it provides a valuation allowance against that excess.

The Company periodically evaluates its tax positions to determine whether it is more likely than not that a tax position will be sustained upon examination by the appropriate taxing authorities. The Company has not incurred any interest or penalties as of September 30, 2016 with respect to uncertain income tax matters. The Company does not expect that there will be unrecognized tax benefits of a significant nature that will increase or decrease within 12 months of the reporting date.

The Company files income tax returns in the U.S. federal and state jurisdictions and in Canada. Management believes that there are no material uncertain tax positions that would impact the accompanying consolidated financial statements. The Company's policy is to recognize interest and penalties related to unrecognized tax benefits in income tax expense. The Company may be subject to examination by the Internal Revenue Service for tax years 2012 through 2015 and by the Canada Revenue Agency for tax years 2012 through 2016. The Company may also be subject to examination on certain state and local jurisdictions for the tax years 2011 through 2015.

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period.

The computation of diluted earnings (loss) per share assumes the conversion, exercise or contingent issuance of securities only when such conversion, exercise or issuance would have a dilutive effect on earnings (loss) per share. The dilutive effect of convertible securities is reflected in diluted earnings per share by application of the “if converted” method. The dilutive effect of outstanding options and warrants and their equivalents is reflected in diluted earnings per share by application of the treasury stock method. Conversion of outstanding warrants, broker units and options would have an antidilutive effect on loss per share for the years ended September 30, 2016 and 2015 and August 31, 2014 and are therefore excluded from the computation of diluted loss per share.

Segments

The Company operates in one reportable segment and, accordingly, no segment disclosures have been presented. All equipment, leasehold improvements and other fixed assets owned by the Company are physically located within the United States (except for insignificant leasehold improvements under evaluation in Baja California, Mexico), and all supply, collaboration and licensing agreements are denominated in U.S. dollars.

Recent Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606), as amended by ASU 2015-14 to defer the effective date (“ASU 2014-09”). ASU 2014-09 creates a new topic in the Accounting Standards Codification (“ASC”) Topic 606 and establishes a new control-based revenue recognition model, changes the basis for deciding when revenue is recognized over time or at a point in time, provides new and more detailed guidance on specific topics, and expands and improves disclosures about revenue. In addition, ASU 2014-09 adds a new Subtopic to the Codification, ASC 340-40, Other Assets and Deferred Costs: Contracts with Customers, to provide guidance on costs related to obtaining a contract with a customer and costs incurred in fulfilling a contract with a customer that are not in the scope of another ASC Topic. The guidance in ASU 2014-09 is effective for public entities for annual reporting periods beginning after December 15, 2017, including interim periods within those years. Early application is only permitted as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Subsequently, the FASB has issued the following standards related to ASU 2014-09: ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (“ASU 2016-08”); ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing (“ASU 2016-10”); and ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”). The Company must adopt ASU 2016-08, ASU 2016-10 and ASU 2016-12 with ASU 2014-09 (collectively, the “new revenue standards”). Management is in the process of assessing the impact of ASU 2014-09 and the new revenue standards on the Company’s consolidated financial statements.

In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. ASU 2014-15 defines management's responsibility to evaluate whether there is substantial doubt about an organization's ability to continue as a going concern and to provide related footnote disclosures. The guidance in ASU 2014-15 is effective for annual reporting periods beginning after December 15, 2016, with early application permitted. Management is in the process of assessing the impact of ASU 2014-15 on the Company’s consolidated financial statements.

In July 2015, FASB issued ASU 2015-11, Simplifying the Measurement of Inventory (Topic 330). ASU 2015-11 indicates that an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The ASU does not apply to inventory measured using LIFO or the retail inventory method. It does apply to all other inventory, including inventory measured using FIFO or average cost. The guidance in ASU 2015-11 is effective for public entities for annual reporting periods beginning after December 15, 2016, including interim periods therein. The provisions should be applied prospectively with early application permitted. Management is in the process of assessing the impact of ASU 2015-11 on the Company’s consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”), which primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The guidance is effective for public entities for fiscal years beginning after December 15, 2017, including interim periods within those years, with early adoption permitted. The Company has not yet determined the impact of ASU 2016-01 on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”), which establishes a new lease accounting model for lessees. The updated guidance requires an entity to recognize assets and liabilities on the balance sheet arising from a lease for both financing and operating leases, along with additional qualitative and quantitative disclosures. The amended guidance is effective for public entities for fiscal years beginning after December 15, 2018, including interim periods within those years, with early adoption permitted. The Company has not yet determined the impact of ASU 2016-02 on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which is part of the FASB's Simplification Initiative. The updated guidance simplifies the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amended guidance is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years, with early adoption permitted. The Company has not yet determined the impact of ASU 2016-09 on its consolidated financial statements.

In May 2016, the FASB issued ASU 2016-11, Revenue Recognition (Topic 605) and Derivatives and Hedging (Topic 815): Rescission of SEC Guidance Because of Accounting Standards Updates 2014-09 and 2014-16 (“ASU 2016-11”), which rescinds certain SEC paragraphs from the FASB Accounting Standards Codification in response to SEC staff announcements at the March 3, 2016 Emerging Issues Task Force meeting, and which supersedes certain SEC observer comments on the topics of revenue and expense recognition for freight service in process, accounting for shipping and handling fees and costs, accounting for consideration given by a vendor to a customer and accounting for gas-balancing arrangements upon the adoption of ASU 2014-09. The effective date for ASU 2016-11 is the same as the effective date of ASU 2014-09 as amended by ASU 2015-14, for annual reporting periods beginning after December 15, 2017, including interim periods within those years. The Company has not yet determined the impact of ASU 2016-11 on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which includes provisions that require financial assets measured at amortized cost basis to be presented at the net amount expected to be collected and credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses, which requires recognition of an estimate of all current expected credit losses. The guidance is effective for public entities for fiscal years beginning after December 15, 2019, including interim periods within those years, with early adoption permitted for fiscal years beginning after December 15, 2018. The Company has not yet determined the impact of ASU 2016-13 on its consolidated financial statements.

Investments

12 Months Ended

Sep. 30, 2016

Investments [Abstract]

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Investments

Short-term investments consisted of the following:

	September 30,		September 30,
	2016		2015

U.S. Treasury Bills	$	3,988,794	$	-
Mutual fund debt securities		-		5,015,171

	$	3,988,794	$	5,015,171

U.S. Treasury Bills are carried at amortized cost which approximates fair value and classified as held-to-maturity investments. Mutual fund debt securities are carried at fair value using level 1 inputs.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Inventory

12 Months Ended

Sep. 30, 2016

Inventory [Abstract]

Inventory Disclosure [Text Block]

Inventory

Raw materials include inventory of manufacturing supplies. Work in process includes manufacturing supplies, direct and indirect labor, contracted manufacturing and testing, and allocated manufacturing overhead for inventory in process at the end of the year. Finished goods include products that are complete and available for sale. At September 30, 2016 and 2015, the Company recorded work in process and finished goods inventory only for those products with recent sales levels to evaluate net realizable value.

Inventory consisted of the following:

	September 30,		September 30,
	2016		2015

Raw materials	$	38,764	$	42,549
Work in process		43,498		137,021
Finished goods		167,168		377,710

	$	249,430	$	557,280

Property, Plant and Equipment, net

12 Months Ended

Sep. 30, 2016

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Property, Plant and Equipment, net

Property, plant and equipment, net consisted of the following:

	September 30,		September 30,
	2016		2015

Aquaculture system	$	126,257	$	124,529
Laboratory facilities		62,033		62,033
Computer and office equipment		102,030		78,936
Tools and equipment		894,319		714,764
Vehicles		49,347		10,997
Leasehold improvements		282,305		123,562
		1,516,291		1,114,821
Less: accumulated depreciation		(793,057)		(643,492)

Depreciable assets, net		723,234		471,329
Construction in progress		32,880		32,079

	$	756,114	$	503,408

Depreciation expense amounted to $149,565, $159,521, $12,529 and $132,122 for the years ended September 30, 2016 and 2015, one month ended September 30, 2014, and year ended August 31, 2014, respectively.

Intangible Assets - Licensing Rights

12 Months Ended

Sep. 30, 2016

Intangible Assets - Licensing Rights [Abstract]

Intangible Assets Disclosure [Text Block]

Intangible Assets - Licensing Rights

In August 2011, the Company acquired an exclusive, worldwide sub-licensable and royalty-free license for certain technology developed under collaboration with a customer. The Company paid a $200,000 license fee for the licensing rights, which are jointly owned by the Company and the customer. The licensing rights do not have a fixed term or termination provisions. The licensing rights were amortized over the estimated useful life of seven years and shown net of accumulated amortization and impairment losses. During the year ended August 31, 2014, the Company discontinued its use of these licensing rights and recorded impairment loss for the remaining value of licensing rights.

Amortization expense amounted to $26,191 for the year ended August 31, 2014. Impairment loss for the year ended August 31, 2014 totaled $90,476 and is included in general and administrative expenses in the accompanying consolidated financial statements.

Commitments

12 Months Ended

Sep. 30, 2016

Commitments [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Commitments

Operating leases

The Company leases buildings and facilities used in its operations under three sublease agreements with the Oxnard Harbor District. In June 2015, the Company exercised its option to extend these sublease agreements for an additional five-year term beginning in October and November 2015. The Company negotiated an option to extend the leases for two additional five-year terms.

The Company leases facilities used for executive offices and laboratories. The Company must pay a portion of the common area maintenance. In July 2016, the Company extended this lease for a two-year term, with options to renew for three successive two-year terms.

The Company leases undeveloped land in Baja California, Mexico to assess the potential development of an additional aquaculture locale and expansion of production. The lease term is three years from June 2015 with options to extend the lease for 30 years. The Company may terminate early with 30 days’ notice. The first two years of rent under the lease totaling $74,606 were prepaid in June 2015, and are not included in the future minimum lease payments below. The Company has a related agreement with the lessor to collaborate on the design, expansion and development of marine aquaculture resources and KLH production facilities on the leased property. Under that agreement, the Company is responsible for certain leasehold improvements including construction of structures and a power-generating facility, which will be owned by the Company. The Company will reimburse the lessor for local operational support. The collaboration agreement expires in June 2018, unless terminated earlier.

Aggregate future minimum lease payments at September 30, 2016 are as follows:

For The Year Ending September 30,
2017	$	185,000
2018		188,000
2019		106,000
2020		106,000
2021		6,000
	$	591,000

Rent expense on these lease agreements amounted to approximately $235,000, $192,000, $15,000 and $181,000 for the years ended September 30, 2016 and 2015, one month ended September 30, 2014, and year ended August 31, 2014, respectively.

Purchase obligations

The Company has commitments totaling approximately $314,000 at September 30, 2016, for signed agreements with contract research organizations, consultants and construction contractors. All purchase obligations are expected to be fulfilled within the next 12 months.

Supply agreements

The Company has two commitments under certain supply agreements with customers for fixed prices per gram on a non-exclusive basis except within that customer’s field of use. One amended and restated supply agreement replaced two prior agreements that automatically renewed each year. The new agreement is effective March 2015 through March 2020 and is renewable for one-year terms upon written request of the customer. The other customer supply agreement is effective October 2014 through October 2019 and is renewable for one-year terms upon written request of the customer.

Joint venture agreement

In May 2016, the Company entered into a joint venture agreement with another party for the formation of a joint venture company to manufacture and sell conjugated therapeutic vaccines. The joint venture is organized as a French simplified corporation.

The Company holds a 30% equity interest in the joint venture in exchange for an initial capital contribution of €120,000. One-half of the initial contribution, approximately $67,000, was paid during the year ended September 30, 2016 with the balance due upon the occurrence of certain defined future events. The Company will also provide the joint venture additional financing as may be required, on a pro rata basis in line with our equity interest. If the joint venture does not achieve certain milestones by December 2017, the joint venture will be dissolved, unless (i) the parties mutually agree to pursue the joint venture arrangement, or (ii) either party decides to purchase the equity interests of the other party. Each of the parties is entitled, upon the occurrence of certain defined events, to acquire the interest of the other party.

In connection with the formation of the joint venture and the execution of its strategy, the parties intend over time to enter into an exclusive supply agreement within a limited field of use for Stellar to supply KLH to the joint venture, a supply agreement designating the joint venture as the exclusive manufacturer and supplier of the other party’s vaccines, and services agreements for the provision of various knowledge and expertise by each of the parties. The other party will also license certain of its intellectual property to the joint venture.

The joint venture has an initial ten-year term, renewable for successive five-year terms. If either party provides notice at least six months prior to the expiration date of an applicable term that it does not wish to continue its participation in the joint venture, the other party will have a right to acquire all of such terminating party’s equity interests in the joint venture.

The joint venture agreement contains customary restrictions on transfer of the equity interests, tag-along and drag-along rights, non-competition, non-solicitation, confidentiality and termination provisions.

Licensing fees

In July 2013, the Company acquired the exclusive, worldwide license to certain patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”). The license agreement required an initial, non-refundable license fee of $25,000, which was paid in fiscal August 2013, and payment of an aggregate of $200,000 in delayed license fees, which were paid in fiscal August 2014. Beginning September 2014, the terms also require a license fee of $20,000 to be paid annually, creditable against royalties due, if any. Royalties are payable for a percentage of related net sales, if any. License fees are also payable for a percentage of related non-royalty sublicensing revenue, if any. No royalties have been incurred to date. The Company also reimbursed patent filing costs of approximately $11,000, $52,000 and $34,000 for the years ended September 30, 2016, September 30, 2015 and August 31, 2014, respectively, and will reimburse certain future patent filing, prosecution, and maintenance costs. There were no patent cost reimbursements during the one month ended September 30, 2014. License fees and patent cost reimbursements have been accounted for as research and development expense in the accompanying consolidated statements of operations.

The license agreement expires when the last valid patent claim licensed under the license agreement expires, which is currently 2030. Prior to that time, the license agreement can be terminated by the licensor upon certain conditions. The Company will have 30 days after written notice from the licensor to cure the problem prior to termination of the license agreement. The Company can terminate the agreement with three months’ prior written notice.

Upon execution of the license agreement, the Company issued 37,120 common shares and warrants to purchase up to 27,840 of the Company’s common shares to the licensor, as further described in Note 9. The warrants expired on January 23, 2015 and were not exercised.

The license agreement provides for the Company to pay up to an aggregate of $6,020,000 in milestone payments to the licensor upon achievement of various financing and development targets up to the first regulatory approval. Remaining contingent milestone payments to the licensor totaling $57,025,000 are related to achievement of sales targets. A financing milestone was met during the year ended August 31, 2014, and accordingly, the Company made a milestone payment of $100,000. No milestones were met during any other annual period, and there can be no assurance that any of the remaining milestones will be met in the future.

Retirement savings plan 401(k) contributions

The Company sponsors a 401(k) retirement savings plan that requires an annual non-elective safe harbor employer contribution of 3% of eligible employee wages. All employees over 21 years of age are eligible beginning the first payroll after 3 consecutive months of employment. Employees are 100% vested in employer contributions and in any voluntary employee contributions. Contributions to the 401(k) plan were approximately $64,000, $58,000, $5,000 and $52,000, for the years ended September 30, 2016, and 2015 one month ended September 30, 2014, and year ended August 31, 2014 respectively.

Related party commitments:

Patent royalty agreement

On August 14, 2002, through its California subsidiary, the Company entered into an agreement with a director and officer of the Company, where he would receive royalty payments in exchange for assignment of his patent rights to the Company. The royalty is 5% of gross receipts from products using this invention in excess of $500,000 annually. The Company’s current operations utilize this invention. Royalty expense incurred during the year ended September 30, 2016 and 2015 was approximately $35,500 and $1,500. There was no royalty expense incurred during the one month ended September 30, 2014 and year ended August 31, 2014.

Collaboration agreement

In December 2013, the Company entered into a collaboration agreement with a privately-held Taiwanese biopharmaceuticals manufacturer effective through December 2015. Under the terms of the agreement, the Company was responsible for the production and delivery of GMP grade KLH for evaluation as a carrier molecule in the collaboration partner’s potential manufacture of OBI-822 active immunotherapy. The Company was also responsible for method development, product formulation, and process qualification for certain KLH reference standards. The collaboration partner was responsible for development objectives and product specifications. The agreement provided for the collaboration partner to pay fees for certain expenses and costs associated with the collaboration. Subject to certain conditions and timing, the collaboration also provided for the parties to negotiate a commercial supply agreement for Stellar KLH™ in the future. However, there can be no assurance that any such negotiations will lead to successful execution of a supply or other agreements related to this collaboration.

The privately-held Taiwanese biopharmaceuticals manufacturer is a beneficial owner of over 5% of the Company’s common shares. In addition, a member of the Company’s Board of Directors currently serves as the manufacturer’s general manager and chair of its board of directors. There are no arrangements or agreements between the Company and the manufacturer relating to representation on the Board.

Share Capital

12 Months Ended

Sep. 30, 2016

Share Capital [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Share Capital

The Company had the following transactions in share capital:

					One Month
	Year Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

Number of common shares issued		2,151,500		42,773		115,100		2,032,269

Issuance of common shares	$	6,750,000	$	-	$	-	$	12,000,000
Share issuance costs		(805,264)		-		-		(907,801)
Proceeds from exercise of warrants		1,368,260		12,609		727,804		3,764,460
Transfer to common shares on exercise of warrants		1,853,581		10,000		890,214		6,591,546
Proceeds from exercise of options		-		94,168		11,488		544,418
Transfer to common shares on exercise of options		-		113,561		13,533		489,136
Share-based compensation		259,379		267,222		36,509		956,634

Performance Shares

There were 1,000,000 common shares allotted as performance shares to be issued to certain officers, directors and employees of the Company based on meeting milestones related to completion of method development for commercial-scale manufacture of KLH, compilation and regulatory submittal of all required chemistry, manufacturing and control data and completion of preclinical toxicity and immunogenicity testing of products under a performance share plan. Share-based compensation was recorded over the estimated vesting period ending in August 2012.

At September 30, 2016, there are 383,838 performance shares reserved for issuance.

License Agreement

During the year ended August 31, 2013, the Company entered into a license agreement and issued 37,120 common shares and warrants to purchase up to 27,840 of the Company’s common shares to the licensor. Each warrant entitled the holder to purchase one common share of the Company at a price of CDN$12.50 per share on or before January 23, 2015. The common shares were subject to a hold period that ended on November 25, 2013. The warrants expired on January 23, 2015 and were not exercised. The value of the shares and warrants were recorded as research and development expense.

Black-Scholes option valuation model

The Company uses the Black-Scholes option valuation model to determine the fair value of warrants, broker units and share options. Option valuation models require the input of highly subjective assumptions including the expected price volatility. The Company has used historical volatility to estimate the volatility of the share price. Changes in the subjective input assumptions can materially affect the fair value estimates, and therefore the existing models do not necessarily provide a reliable single measure of the fair value of the Company’s warrants, broker units and share options.

Warrants

A summary of the Company’s warrants activity is as follows:

			Weighted
	Number of		Average
	Warrants		Exercise Price

Balance - September 30, 2014		1,054,531	$	9.05

Exercised		(3,900)		4.05	CDN $
Expired		(27,870)		12.50	CDN $

Balance - September 30, 2015		1,022,761	$	9.04

Granted		1,265,626		4.50
Granted		40,000		4.00	CDN $
Exercised		(424,000)		4.00	CDN $
Expired		(598,761)		13.33
Expired		(40,000)		4.00	CDN $

Balance - September 30, 2016		1,265,626	$	4.50

There are no outstanding warrants with exercise prices denominated in Canadian dollar at September 30, 2016.

The weighted average contractual life remaining on the outstanding warrants at September 30, 2016 is 63 months.

The following table summarizes information about the warrants outstanding at September 30, 2016:

* Exercisable beginning January 6, 2017.

Warrant Liability

All warrants with exercise prices denominated in Canadian dollars were exercised or expired. Therefore, there is no outstanding warrant liability at September 30, 2016.

Equity offerings conducted by the Company in prior years included the issuance of warrants with exercise prices denominated in Canadian dollars. The Company’s functional currency is in U.S. dollars. As a result of having exercise prices denominated in other than the Company’s functional currency, those warrants met the definition of derivatives and were therefore classified as derivative liabilities measured at fair value with adjustments to fair value recognized through the consolidated statements of operations. As these warrants were exercised, the fair value of the recorded warrant liability on date of exercise was included in common shares along with the proceeds from the exercise. If those warrants expired, the related decrease in warrant liability was recognized in profit or loss, as part of the change in fair value of warrant liability. There was no cash flow impact as a result of this accounting treatment.

The fair value of these warrants was determined using the Black-Scholes option valuation model at the end of each reporting period. Upon exercise of the warrants, the fair value of warrants included in derivative liabilities was reclassified to equity.

The fair value of warrants exercised was determined using the Black-Scholes option valuation model, using the following weighted average assumptions:

							One Month
	Year Ended						Ended			Year Ended
	September 30,			September 30,			September 30,			August 31,
	2016			2015			2014			2014
Risk free interest rate		0.48	%		0.44	%		1.12	%		1.07	%
Expected life (years)		0.04			0.4			0.03			0.27
Expected share price volatility		92	%		92	%		97	%		106	%

There were no warrants granted during the year ended September 30, 2015 or the one month ended September 30, 2014. The fair value of warrants granted was determined using the Black-Scholes option valuation model, using the following weighted average assumptions at the date of the grant:

	Year Ended			Year Ended
	September 30,			August 31,
	2016			2014
Risk free interest rate		0.52	%		1.48	%
Expected life (years)		0.01			3.00
Expected share price volatility		91	%		112	%
Expected dividend yield		0	%		0	%

Broker units

The Company granted broker units as finders’ fees in conjunction with equity offerings in prior years. Broker units were fully vested when granted and allowed the holders to purchase equity units. A unit consisted of one common share and either one whole warrant or one half warrant.

A summary of broker units activity is as follows:

			Weighted
	Number of		Average
	Units		Exercise Price

Balance - September 30, 2014		46,720	$	2.25

Exercised		(120)		5.00	CDN $

Balance - September 30, 2015		46,600		1.87

Exercised		(40,000)		2.50	CDN $
Expired		(6,600)		2.50	CDN $

Balance - September 30, 2016		-	$	-

There were no broker units granted during the years ended September 30, 2016 and 2015, the one month ended September 30, 2014, or the year ended August 31, 2014.

Options

The Company has a fixed share option plan adopted in 2013 (“the Plan”) to be administered by the Board of Directors, which has the discretion to grant up to an aggregate of 1,000,000 options. The exercise price of an option is set at the closing price of the Company’s common shares on the date of grant. Share options granted to directors, officers, employees and consultants are subject to the following vesting schedule:

(a)

One-third shall vest immediately;

(b)

One-third shall vest 12 months from the date of grant; and

(c)

One-third shall vest 18 months from the date of grant.

Share options granted to investor relations consultants vest over a period of not less than 12 months as to 25% on the date that is three months from the date of grant, and a further 25% on each successive date that is three months from the date of the prior vesting.

Options have been issued under the Plan allowing the holders to purchase common shares of the Company as follows:

			Weighted
	Number of		Average
	Options		Exercise Price

Balance - September 30, 2014		588,553	$	5.56

Granted		16,500		13.30	CDN $
Exercised		(38,750)		3.06	CDN $
Expired		(3,333)		18.30
Expired		(5,332)		7.76	CDN $

Balance - September 30, 2015		557,638	$	5.17

Granted		56,300		6.47
Expired		(21,334)		10.70
Expired		(53,501)		5.22	CDN $

Balance - September 30, 2016		539,103	$	5.29

The weighted average contractual life remaining on the outstanding options is 2.57 years.

The following table summarizes information about the options under the Plan outstanding and exercisable at September 30, 2016:

		Exercisable at
Number of Options		September 30, 2016		Range of exercise prices	Expiry Dates
	283,610		283,610	CDN$0.01 - 5.00	Apr 2017-Dec 2019
	8,600		2,867	$0.01 - 5.00	Sep 2023
	142,860		141,193	CDN$5.01 - 10.00	Oct 2017-Jun 2022
	33,033		15,900	$5.01 - 10.00	Dec 2022
	21,500		21,500	CDN$15.01 - 20.00	Nov 2018-Nov 2021
	49,500		49,500	$15.01 - 20.00	Nov 2020
	539,103		514,570

There were no share options granted in the one month ended September 30, 2014. The estimated fair value of the share options granted was determined using a Black-Scholes option valuation model with the following weighted average assumptions:

	Year Ended						Year Ended
	September 30,			September 30,			August 31,
	2016			2015			2014
Risk free interest rate		1.01	%		1.65	%		2.01	%
Expected life (years)		7.00			7.00			6.75
Expected share price volatility		117	%		115	%		120	%
Expected dividend yield		0	%		0	%		0	%

The weighted average fair value of share options granted during the years ended September 30, 2016 and 2015, and August 31, 2014 was $5.56, $9.48, and $15.14, respectively.

As of September 30, 2016, the Company had approximately $86,000 of unrecognized share-based compensation expense, which is expected to be recognized over a period of 1.5 years.

The intrinsic value of the options exercised during the year ended September 30, 2015, one month ended September 30, 2014, and year ended August 31, 2014, was $8.28, $15.99, and $12.78, respectively. There were no options exercised during the year ended September 30, 2016. The intrinsic value of the vested options at September 30, 2016 was $0.10.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Income Taxes

12 Months Ended

Sep. 30, 2016

Income Taxes [Abstract]

Income Tax Disclosure [Text Block]

10.

Income Taxes

The breakdown of loss before income tax by jurisdiction is as follows:

						One Month
	Year Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

U.S.	$	(4,001,206)	$	(3,258,355)	$	(334,841)	$	(4,183,392)
Canadian		(1,026,520)		405,203		1,462,652		(4,096,931)
Other foreign		8,846		46,923		3,893		(132,000)

Total Loss Before Income Tax	$	(5,018,880)	$	(2,806,229)	$	1,131,704	$	(8,412,323)

Deferred income tax assets and liabilities of the Company are as follows:

	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

Deferred income tax assets:
Non-capital loss carry-forwards	$	10,000,000	$	8,028,900	$	6,561,000	$	6,418,300
Research and development tax credits		808,000		716,400		626,900		616,600
Deferred expenses		70,000		82,900		84,000		90,000
Property, plant and equipment		400		1,700		-		-
Share issuance costs		207,200		67,800		124,700		131,800
Deferred income tax liabilities:
U.S. federal benefit net of state taxes		(764,500)		(628,800)		(517,100)		(509,000)
Property, plant and equipment		-		-		(13,600)		(14,500)
Valuation allowance		(10,321,100)		(8,268,900)		(6,865,900)		(6,733,200)

Net deferred income tax asset (liability)	$	-	$	-	$	-	$	-

Realization of the deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance.

As of September 30, 2016, the Company had federal net operating loss (“NOL”) carryforwards of approximately $20,708,000 expiring 2030 through 2036, California NOL carryforwards of approximately $20,472,000 expiring 2018 through 2036, and Canadian federal and provincial NOL carryforwards of approximately CDN$5,855,000 expiring 2029 through 2036. Portions of these NOL carryforwards may be used to offset future taxable income, if any.

As of September 30, 2016, the Company also has federal and California research and development tax credit carryforwards of approximately $384,000 and $424,000, respectively, available to offset future taxes. The federal credits begin expiring in 2030 and continue expiring through 2036. The state tax credits do not expire.

Under the provisions of Section 382 of the Internal Revenue Code, substantial changes in the Company's ownership limit the amount of net operating loss carryforwards and tax credit carryforwards that can be utilized annually in the future to offset taxable income. A valuation allowance has been established to reserve the potential benefits of these carryforwards in the Company's consolidated financial statements to reflect the uncertainty of future taxable income required to utilize available tax loss carryforwards and other deferred tax assets.

The recovery of income taxes shown in the consolidated statements of operations differs from the amounts obtained by applying statutory rates to the loss before provision for income taxes due to the following:

							One Month
	Year Ended						Ended			Year Ended
	September 30,			September 30,			September 30,			August 31,
	2016			2015			2014			2014

Combined Canadian federal and provincial tax rates		26.0	%		26.0	%		26.0	%		26.0	%

Expected income tax (recovery)/expense	$	(1,304,900)		$	(729,600)		$	294,300		$	(2,187,200)

Nondeductible share-based payments		(67,400)			69,500			9,500			248,700
Nondeductible change in fair value of warrant liability		(55,100)			(554,100)			(436,800)			659,300
Effect of higher income tax rate in U.S.		(550,600)			(445,800)			(46,000)			(602,100)
Foreign currency differences		20,000			169,900			25,400			(50,900)
Other		(2,800)			(43,300)			(3,800)			(219,800)
Change in valuation allowance on deferred tax assets		1,968,000			1,570,200			161,200			2,179,200

Income tax expense	$	7,200		$	36,800		$	3,800		$	27,200

The components of income tax provision (benefits) are as follows:

					One Month
	Year Ended				Ended		Year Ended
	September 30, 2016		September 30, 2015		September 30, 2014		August 31, 2014

Current tax provision
U.S. federal	$	-	$	-	$	-	$	-
Canadian		-		-		-		-
Other foreign		6,400		36,000		3,000		26,400
State		800		800		800		800

Deferred tax provision
U.S. federal		(1,265,700)		(1,032,200)		(107,100)		(1,431,400)
Canadian		(303,300)		(209,300)		(21,600)		(289,800)
State		(399,000)		(328,700)		(32,500)		(458,000)

Change in valuation allowance on deferred tax assets		1,968,000		1,570,200		161,200		2,179,200

Total	$	7,200	$	36,800	$	3,800	$	27,200

Supplemental Disclosure of Cash Flow and Non-Cash Transactions

12 Months Ended

Sep. 30, 2016

Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]

11.

Supplemental Disclosure of Cash Flow and Non-Cash Transactions

Supplemental disclosure of cash flow information follows:

					One Month
	Years Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014
Cash paid during the period for taxes	$	7,200	$	36,800	$	800	$	30,200

Supplemental disclosure of non-cash financing and investing activities follows:

					One Month
	Years Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

Share issuance costs - broker units and warrants	$	-	$	-	$	-	$	386,898
Share issuance costs withheld from escrow proceeds		472,500		-		-		386,325
Transfer to common shares on exercise of warrants		1,853,581		10,000		890,214		6,591,546
Transfer to common shares on exercise of options		-		113,561		13,533		489,136
Transfer to common shares on issuance of performance shares		-		-		-		422,728
Shares subscribed transferred to common shares		-		-		-		5,155,674

Fair Value of Financial Instruments

12 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

12.

Fair Value of Financial Instruments

Fair value of a financial instrument is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The carrying value of certain financial instruments such as accounts receivable, accounts payable, accrued liabilities, and deferred revenue approximates fair value due to the short-term nature of such instruments. Short-term investments in U.S. Treasury Bills are reported at amortized cost, which approximates fair value.

The Company follows the fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three levels of inputs that may be used to measure fair value:

Level 1:

Quoted prices in active markets for identical or similar assets and liabilities.

Level 2:

Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities.

Level 3:

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The Company recorded its short-term investments in mutual fund debt securities at fair value using Level 1 inputs in the fair value hierarchy. The Company recorded its warrant liability at fair value using Level 2 inputs using the Black-Scholes option valuation model and assumptions disclosed in Note 9.

The following table summarizes fair values for those assets and liabilities with fair value measured on a recurring basis. There are no short-term investments in mutual fund debt securities or warrant liability at September 30, 2016.

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value

September 30, 2016
Assets
Short-term investments in U.S. Treasury Bills	$	3,988,794	$	-	$	-	$	3,988,794

September 30, 2015
Assets
Short-term investments in mutual fund debt securities	$	5,015,171	$	-	$	-	$	5,015,171
Liabilities
Warrant liability, current portion		-		1,550,630		-		1,550,630

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Concentrations of Credit Risk

12 Months Ended

Sep. 30, 2016

Concentrations of Credit Risk [Abstract]

Concentration Risk Disclosure [Text Block]

13.

Concentrations of Credit Risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, US Treasury bills, mutual fund debt securities and accounts receivable. The Company estimates its maximum credit risk at the amount recorded on the balance sheet.

Management’s assessment of the Company’s credit risk for cash and cash equivalents is low as they are held in major financial institutions believed to be credit worthy or US Treasury bills. The Company limits its exposure to credit loss for short-term investments by using US Treasury bills or a mutual fund that invests in high-quality, U.S. dollar-denominated short-term fixed-, floating- and variable-rate debt securities that have received either a minimum short-term rating of at least A-1 (or its equivalent) or a minimum long-term rating of A minus (or its equivalent), by one or more Nationally Recognized Statistical Ratings Organizations, or, if unrated, that are deemed by the fund to be of comparable quality at the time of purchase. Based on credit monitoring and history, the Company considers the risk of credit losses due to customer non-performance on accounts receivable to be low.

The Company had the following concentrations of revenues by customers and grantors:

One Month

Year Ended

Ended

Year Ended

September 30,

August 31,

2016

2015

2014

76% from

82% from

86% from

73% from

Product sales and contract services revenue

3 customers

2 customers

100% from

Grant revenue

1 grantor

The Company had the following concentrations of revenues by geographic areas:

							One Month
	Year Ended						Ended			Year Ended
	September 30,			September 30,			September 30,			August 31,
	2016			2015			2014			2014

Europe		43	%		53	%		9	%		41	%
Asia		45	%		38	%		28	%		40	%
U.S.		12	%		9	%		62	%		14	%
Other countries		-			-			-			6	%

The Company had the following concentrations of accounts receivable:

	September 30,	September 30,
	2016	2015

	100% from	91% from
Accounts receivable	1 customer	2 customers

Reclassifications

12 Months Ended

Sep. 30, 2016

Reclassifications [Abstract]

Disclosure of Reclassification Amount [Text Block]

14.

Reclassifications

Certain reclassifications have been made to the prior period to conform with the current period’s presentation. These include the Company’s reclassification of a mutual fund investing in short-term debt securities from cash equivalents to short-term investments and reclassification of costs related to aquaculture to present such costs separately from costs of sales and contract services. There was no impact on total assets, total shareholders’ equity, accumulated deficit, total expenses or net income (loss) resulting from these reclassifications. The statement of cash flows reflects the mutual fund activity as cash flows from investing activities rather than changes in cash.

- Definition

The entire disclosure for any adjustments made during the period to avoid double counting in comprehensive income items displayed as part of net income that also had been displayed as part of other comprehensive income in that period or earlier periods. These adjustments include reclassifications to net income of items in accumulated comprehensive income, such as deferred gains or losses on qualifying hedges when hedged item reported in net income, holding gains or losses on available-for-sale securities transferred into trading category, unrealized holding gains or losses on debt securities transferred from held-to-maturity category into available-for-sale category and accumulated translation adjustment attributable to foreign subsidiary or investment in foreign entity upon sale or liquidation.

+ References + Details

Significant Accounting Policies (Policies)

12 Months Ended

Sep. 30, 2016

Significant Accounting Policies [Abstract]

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

Investment, Policy [Policy Text Block]

Investments

Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Allowance for Doubtful Accounts Receivable

Inventory, Policy [Policy Text Block]

Inventory

Property, Plant and Equipment, Policy [Policy Text Block]

Property, Plant and Equipment

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Fair Value of Financial Instruments, Policy [Policy Text Block]

Fair Value of Financial Instruments

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

Product Sales

Contract services revenue

Grants

Research and Development Expense, Policy [Policy Text Block]

Research and Development

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]

Share-Based Compensation

The Company grants options to buy common shares of the Company to its directors, officers, employees and consultants, and grants other equity-based instruments to non-employees.

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Exchange

Transactions in currencies other than the U.S. dollar are recorded at exchange rates prevailing on the dates of the transactions.

Income Tax, Policy [Policy Text Block]

Income Taxes

Earnings Per Share, Policy [Policy Text Block]

Earnings (Loss) Per Share

Basic earnings (loss) per share is calculated by dividing income available to common shareholders by the weighted average number of common shares outstanding during the period.

Segment Reporting, Policy [Policy Text Block]

Segments

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

Investments (Tables)

12 Months Ended

Sep. 30, 2016

Investments [Abstract]

Schedule Of Short Term Investments [Table Text Block]

Short-term investments consisted of the following:

	September 30,		September 30,
	2016		2015

U.S. Treasury Bills	$	3,988,794	$	-
Mutual fund debt securities		-		5,015,171

	$	3,988,794	$	5,015,171

Inventory (Tables)

12 Months Ended

Sep. 30, 2016

Inventory [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventory consisted of the following:

	September 30,		September 30,
	2016		2015

Raw materials	$	38,764	$	42,549
Work in process		43,498		137,021
Finished goods		167,168		377,710

	$	249,430	$	557,280

Property, Plant and Equipment, net (Tables)

12 Months Ended

Sep. 30, 2016

Property, Plant and Equipment, net [Abstract]

Property, Plant and Equipment [Table Text Block]

Property, plant and equipment, net consisted of the following:

	September 30,		September 30,
	2016		2015

Aquaculture system	$	126,257	$	124,529
Laboratory facilities		62,033		62,033
Computer and office equipment		102,030		78,936
Tools and equipment		894,319		714,764
Vehicles		49,347		10,997
Leasehold improvements		282,305		123,562
		1,516,291		1,114,821
Less: accumulated depreciation		(793,057)		(643,492)

Depreciable assets, net		723,234		471,329
Construction in progress		32,880		32,079

	$	756,114	$	503,408

Commitments (Tables)

12 Months Ended

Sep. 30, 2016

Commitments [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

Aggregate future minimum lease payments at September 30, 2016 are as follows:

For The Year Ending September 30,
2017	$	185,000
2018		188,000
2019		106,000
2020		106,000
2021		6,000
	$	591,000

Share Capital (Tables)

12 Months Ended

Sep. 30, 2016

Class of Warrant or Right [Line Items]

Schedule of Stockholders Equity [Table Text Block]

The Company had the following transactions in share capital:

					One Month
	Year Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

Number of common shares issued		2,151,500		42,773		115,100		2,032,269

Issuance of common shares	$	6,750,000	$	-	$	-	$	12,000,000
Share issuance costs		(805,264)		-		-		(907,801)
Proceeds from exercise of warrants		1,368,260		12,609		727,804		3,764,460
Transfer to common shares on exercise of warrants		1,853,581		10,000		890,214		6,591,546
Proceeds from exercise of options		-		94,168		11,488		544,418
Transfer to common shares on exercise of options		-		113,561		13,533		489,136
Share-based compensation		259,379		267,222		36,509		956,634

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of the Company’s warrants activity is as follows:

			Weighted
	Number of		Average
	Warrants		Exercise Price

Balance - September 30, 2014		1,054,531	$	9.05

Exercised		(3,900)		4.05	CDN $
Expired		(27,870)		12.50	CDN $

Balance - September 30, 2015		1,022,761	$	9.04

Granted		1,265,626		4.50
Granted		40,000		4.00	CDN $
Exercised		(424,000)		4.00	CDN $
Expired		(598,761)		13.33
Expired		(40,000)		4.00	CDN $

Balance - September 30, 2016		1,265,626	$	4.50

Schedule Of Warrants Outstanding [Table Text Block]

The following table summarizes information about the warrants outstanding at September 30, 2016:

* Exercisable beginning January 6, 2017.

Schedule of Broker Units, Activity [Table Text Block]

A summary of broker units activity is as follows:

			Weighted
	Number of		Average
	Units		Exercise Price

Balance - September 30, 2014		46,720	$	2.25

Exercised		(120)		5.00	CDN $

Balance - September 30, 2015		46,600		1.87

Exercised		(40,000)		2.50	CDN $
Expired		(6,600)		2.50	CDN $

Balance - September 30, 2016		-	$	-

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Options have been issued under the Plan allowing the holders to purchase common shares of the Company as follows:

			Weighted
	Number of		Average
	Options		Exercise Price

Balance - September 30, 2014		588,553	$	5.56

Granted		16,500		13.30	CDN $
Exercised		(38,750)		3.06	CDN $
Expired		(3,333)		18.30
Expired		(5,332)		7.76	CDN $

Balance - September 30, 2015		557,638	$	5.17

Granted		56,300		6.47
Expired		(21,334)		10.70
Expired		(53,501)		5.22	CDN $

Balance - September 30, 2016		539,103	$	5.29

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]

The following table summarizes information about the options under the Plan outstanding and exercisable at September 30, 2016:

		Exercisable at
Number of Options		September 30, 2016		Range of exercise prices	Expiry Dates
	283,610		283,610	CDN$0.01 - 5.00	Apr 2017-Dec 2019
	8,600		2,867	$0.01 - 5.00	Sep 2023
	142,860		141,193	CDN$5.01 - 10.00	Oct 2017-Jun 2022
	33,033		15,900	$5.01 - 10.00	Dec 2022
	21,500		21,500	CDN$15.01 - 20.00	Nov 2018-Nov 2021
	49,500		49,500	$15.01 - 20.00	Nov 2020
	539,103		514,570

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The estimated fair value of the share options granted was determined using a Black-Scholes option valuation model with the following weighted average assumptions:

	Year Ended						Year Ended
	September 30,			September 30,			August 31,
	2016			2015			2014
Risk free interest rate		1.01	%		1.65	%		2.01	%
Expected life (years)		7.00			7.00			6.75
Expected share price volatility		117	%		115	%		120	%
Expected dividend yield		0	%		0	%		0	%

Warrants Exercised [Member]

Class of Warrant or Right [Line Items]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The fair value of warrants exercised was determined using the Black-Scholes option valuation model, using the following weighted average assumptions:

							One Month
	Year Ended						Ended			Year Ended
	September 30,			September 30,			September 30,			August 31,
	2016			2015			2014			2014
Risk free interest rate		0.48	%		0.44	%		1.12	%		1.07	%
Expected life (years)		0.04			0.4			0.03			0.27
Expected share price volatility		92	%		92	%		97	%		106	%

Warrants Granted [Member]

Class of Warrant or Right [Line Items]

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]

The fair value of warrants granted was determined using the Black-Scholes option valuation model, using the following weighted average assumptions at the date of the grant:

	Year Ended			Year Ended
	September 30,			August 31,
	2016			2014
Risk free interest rate		0.52	%		1.48	%
Expected life (years)		0.01			3.00
Expected share price volatility		91	%		112	%
Expected dividend yield		0	%		0	%

Income Taxes (Tables)

12 Months Ended

Sep. 30, 2016

Income Taxes [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

The breakdown of loss before income tax by jurisdiction is as follows:

						One Month
	Year Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

U.S.	$	(4,001,206)	$	(3,258,355)	$	(334,841)	$	(4,183,392)
Canadian		(1,026,520)		405,203		1,462,652		(4,096,931)
Other foreign		8,846		46,923		3,893		(132,000)

Total Loss Before Income Tax	$	(5,018,880)	$	(2,806,229)	$	1,131,704	$	(8,412,323)

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

Deferred income tax assets and liabilities of the Company are as follows:

	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

Deferred income tax assets:
Non-capital loss carry-forwards	$	10,000,000	$	8,028,900	$	6,561,000	$	6,418,300
Research and development tax credits		808,000		716,400		626,900		616,600
Deferred expenses		70,000		82,900		84,000		90,000
Property, plant and equipment		400		1,700		-		-
Share issuance costs		207,200		67,800		124,700		131,800
Deferred income tax liabilities:
U.S. federal benefit net of state taxes		(764,500)		(628,800)		(517,100)		(509,000)
Property, plant and equipment		-		-		(13,600)		(14,500)
Valuation allowance		(10,321,100)		(8,268,900)		(6,865,900)		(6,733,200)

Net deferred income tax asset (liability)	$	-	$	-	$	-	$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

							One Month
	Year Ended						Ended			Year Ended
	September 30,			September 30,			September 30,			August 31,
	2016			2015			2014			2014

Combined Canadian federal and provincial tax rates		26.0	%		26.0	%		26.0	%		26.0	%

Expected income tax (recovery)/expense	$	(1,304,900)		$	(729,600)		$	294,300		$	(2,187,200)

Nondeductible share-based payments		(67,400)			69,500			9,500			248,700
Nondeductible change in fair value of warrant liability		(55,100)			(554,100)			(436,800)			659,300
Effect of higher income tax rate in U.S.		(550,600)			(445,800)			(46,000)			(602,100)
Foreign currency differences		20,000			169,900			25,400			(50,900)
Other		(2,800)			(43,300)			(3,800)			(219,800)
Change in valuation allowance on deferred tax assets		1,968,000			1,570,200			161,200			2,179,200

Income tax expense	$	7,200		$	36,800		$	3,800		$	27,200

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

The components of income tax provision (benefits) are as follows:

					One Month
	Year Ended				Ended		Year Ended
	September 30, 2016		September 30, 2015		September 30, 2014		August 31, 2014

Current tax provision
U.S. federal	$	-	$	-	$	-	$	-
Canadian		-		-		-		-
Other foreign		6,400		36,000		3,000		26,400
State		800		800		800		800

Deferred tax provision
U.S. federal		(1,265,700)		(1,032,200)		(107,100)		(1,431,400)
Canadian		(303,300)		(209,300)		(21,600)		(289,800)
State		(399,000)		(328,700)		(32,500)		(458,000)

Change in valuation allowance on deferred tax assets		1,968,000		1,570,200		161,200		2,179,200

Total	$	7,200	$	36,800	$	3,800	$	27,200

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Tables)

12 Months Ended

Sep. 30, 2016

Supplemental Disclosure of Cash Flow and Non-Cash Transactions [Abstract]

Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]

Supplemental disclosure of cash flow information follows:

					One Month
	Years Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014
Cash paid during the period for taxes	$	7,200	$	36,800	$	800	$	30,200

Schedule of Other Significant Noncash Transactions [Table Text Block]

Supplemental disclosure of non-cash financing and investing activities follows:

					One Month
	Years Ended				Ended		Year Ended
	September 30,		September 30,		September 30,		August 31,
	2016		2015		2014		2014

Share issuance costs - broker units and warrants	$	-	$	-	$	-	$	386,898
Share issuance costs withheld from escrow proceeds		472,500		-		-		386,325
Transfer to common shares on exercise of warrants		1,853,581		10,000		890,214		6,591,546
Transfer to common shares on exercise of options		-		113,561		13,533		489,136
Transfer to common shares on issuance of performance shares		-		-		-		422,728
Shares subscribed transferred to common shares		-		-		-		5,155,674

Fair Value of Financial Instruments (Tables)

12 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value Measurements Using
	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value

September 30, 2016
Assets
Short-term investments in U.S. Treasury Bills	$	3,988,794	$	-	$	-	$	3,988,794

September 30, 2015
Assets
Short-term investments in mutual fund debt securities	$	5,015,171	$	-	$	-	$	5,015,171
Liabilities
Warrant liability, current portion		-		1,550,630		-		1,550,630

Concentrations of Credit Risk (Tables)

12 Months Ended

Sep. 30, 2016

Concentrations of Credit Risk [Abstract]

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

The Company had the following concentrations of revenues by customers and grantors:

One Month

Year Ended

Ended

Year Ended

September 30,

August 31,

2016

2015

2014

76% from

82% from

86% from

73% from

Product sales and contract services revenue

3 customers

2 customers

100% from

Grant revenue

1 grantor

The Company had the following concentrations of revenues by geographic areas:

							One Month
	Year Ended						Ended			Year Ended
	September 30,			September 30,			September 30,			August 31,
	2016			2015			2014			2014

Europe		43	%		53	%		9	%		41	%
Asia		45	%		38	%		28	%		40	%
U.S.		12	%		9	%		62	%		14	%
Other countries		-			-			-			6	%

The Company had the following concentrations of accounts receivable:

	September 30,	September 30,
	2016	2015

	100% from	91% from
Accounts receivable	1 customer	2 customers

Nature of Operations (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
Nature of Operations (Details Textual) - USD ($)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014	Sep. 02, 2015
Nature of Operations [Line Items]
Net Income (Loss)	$ 1,127,904	$ (5,026,080)	$ (2,843,029)	$ (8,439,523)
Accumulated deficit		(40,361,395)	(35,335,315)
Working capital		11,500,000
Proceeds from issuance of common shares, net		6,750,000		7,000,000
Gain (Loss) in fair value of warrant liability	$ 1,680,040	$ (211,956)	$ 2,131,062	$ (2,533,305)
Common Stock, Shares, Outstanding		10,136,258	7,984,758
Stockholders' Equity Note, Stock Split		As a result of the reverse split, every ten shares of the issued and outstanding common shares, without par value, consolidated into one newly-issued outstanding common share, without par value. Each fractional share remaining after the reverse split that was less than one-half of a share was cancelled and each fractional share that was at least one-half of a share was changed to one whole share.
Before Reverse Split Adjustment [Member]
Nature of Operations [Line Items]
Common Stock, Shares, Outstanding			7,984,758		79,847,550

Significant Accounting Policies (Details Textual)	12 Months Ended
Significant Accounting Policies (Details Textual)	Sep. 30, 2016
Minimum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	1 year 6 months
Maximum [Member]
Significant Accounting Policies Disclosure [Line Items]
Property, plant and equipment, useful lives	15 years

Investments (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
U.S. Treasury Bills	$ 3,988,794	$ 0
Mutual fund debt securities	0	5,015,171
Total short-term investments	$ 3,988,794	$ 5,015,171

Inventory (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Raw materials	$ 38,764	$ 42,549
Work in process	43,498	137,021
Finished goods	167,168	377,710
Inventory	$ 249,430	$ 557,280

Property, Plant and Equipment, net (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 1,516,291	$ 1,114,821
Less: accumulated depreciation	(793,057)	(643,492)
Depreciable assets, net	723,234	471,329
Construction in progress	32,880	32,079
Property, plant and equipment, net	756,114	503,408
Aquaculture system [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	126,257	124,529
Laboratory facilities [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	62,033	62,033
Computer and office equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	102,030	78,936
Tools and equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	894,319	714,764
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	49,347	10,997
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Depreciable assets, gross	$ 282,305	$ 123,562

Property, Plant and Equipment, net (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 12,529	$ 149,565	$ 159,521	$ 132,122

Intangible Assets - Licensing Rights (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014	Aug. 31, 2011
Acquired Finite-Lived Intangible Assets [Line Items]
Amortization expense				$ 26,191
Impairment loss	$ 0	$ 0	$ 0	$ 90,476
Licensing Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Licence fee for the licensing rights					$ 200,000

Commitments (Details)	Sep. 30, 2016 USD ($)
For The Year Ending September 30,
2017	$ 185,000
2018	188,000
2019	106,000
2020	106,000
2021	6,000
Future minimum lease payments, total	$ 591,000

Commitments (Details Textual)	1 Months Ended		12 Months Ended
Commitments (Details Textual)	Jun. 30, 2015 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Aug. 31, 2014 USD ($)	Aug. 31, 2013 USD ($) shares	Sep. 30, 2016 EUR (€)	Aug. 14, 2002 USD ($)
Other Commitments [Line Items]
Rent expense on lease agreements		$ 15,000	$ 235,000	$ 192,000	$ 181,000
Equity Method Investments			$ 66,695	0
Joint venture agreement [Member]
Other Commitments [Line Items]
Equity Method Investments Committed Capital \| €							€ 120,000
Equity Method Investment, Ownership Percentage			30.00%				30.00%
Equity Method Investments			$ 67,000
Director and Officer [Member] \| Royalty Agreements [Member]
Other Commitments [Line Items]
Royalty percentage of gross receipts over base amount								5.00%
Gross receipt base amount for royalty calculation								$ 500,000
Royalty expense			35,500	1,500
Licensing Agreements [Member]
Other Commitments [Line Items]
License costs					200,000	$ 25,000
Annual license fee		20,000
Patent cost reimbursement			11,000	52,000	34,000
Common shares issued upon execution of licence agreement \| shares						37,120
Common shares to be called by warrants \| shares						27,840
Aggregate milestone payments upon achievement of financing and development targets			6,020,000
Contingent milestone payments due upon achievement of sales target			$ 57,025,000
Milestone payment					100,000
Collaborative Agreement [Member] \| A Taiwan Biopharmaceuticals Manufacturer and a Beneficial Owner [Member]
Other Commitments [Line Items]
Ownership percentage			5.00%				5.00%
401(k) Retirement Savings Plan [Member]
Other Commitments [Line Items]
Employer contributions		$ 5,000	$ 64,000	$ 58,000	$ 52,000
Employee vesting percentage			100.00%
Annual non-elective safe harbor employer contribution			3.00%
Agreements With Contract Manufacturing Organizations And Consultants [Member]
Other Commitments [Line Items]
Purchase obligations			$ 314,000
Three buildings and facilities used in its operations [Member]
Other Commitments [Line Items]
Lease agreement, contract term			5 years
Lease agreement, renewal term			5 years
Facilities used for executive offices and laboratories [Member]
Other Commitments [Line Items]
Lease agreement, renewal term			2 years
Undeveloped land in Baja, Mexico
Other Commitments [Line Items]
Lease agreement, contract term			3 years
Rent prepaid in June 2015	$ 74,606

Share Capital (Details) - USD ($)	1 Months Ended	12 Months Ended
Share Capital (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Class of Warrant or Right [Line Items]
Issuance of common shares		$ 6,750,000		$ 7,000,000
Share issuance costs		(805,264)
Proceeds from exercise of warrants	$ 727,804	1,368,260	$ 12,609	3,764,460
Transfer to common shares on exercise of warrants	860,397	1,762,586	9,574	6,591,546
Proceeds from exercise of options	11,488		94,168	544,418
Transfer to common shares on exercise of options	13,533	0	113,561	489,136
Share-based compensation	$ 36,509	$ 259,379	$ 267,222	$ 956,634
Share Capital [Member]
Class of Warrant or Right [Line Items]
Number of common shares issued	115,100	2,151,500	42,773	2,032,269
Issuance of common shares	$ 0	$ 6,750,000	$ 0	$ 12,000,000
Share issuance costs	0	(805,264)	0	(907,801)
Proceeds from exercise of warrants	727,804	1,368,260	12,609	3,764,460
Transfer to common shares on exercise of warrants	890,214	1,853,581	10,000	6,591,546
Proceeds from exercise of options	11,488	0	94,168	544,418
Transfer to common shares on exercise of options	13,533	0	113,561	489,136
Share-based compensation	$ 36,509	$ 259,379	$ 267,222	$ 956,634

Share Capital (Details 1)	12 Months Ended
Share Capital (Details 1)	Sep. 30, 2016 $ / shares shares	Sep. 30, 2016 $ / shares shares	Sep. 30, 2015 $ / shares shares	Sep. 30, 2015 $ / shares shares
Class of Warrant or Right [Line Items]
Number of Warrants, Beginning Balance	1,022,761	1,022,761	1,054,531	1,054,531
Number of Warrants, Granted	1,265,626	1,265,626
Number of Warrants, Granted	40,000	40,000
Number of Warrants, Exercised	(424,000)	(424,000)	(3,900)	(3,900)
Number of Warrants, Expired	(598,761)	(598,761)	(27,870)	(27,870)
Number of Warrants, Expired	(40,000)	(40,000)
Number of Warrants, Ending Balance	1,265,626	1,265,626	1,022,761	1,022,761
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 9.04		$ 9.05
Weighted Average Exercise Price, Granted \| (per share)	4.50	$ 4.00
Weighted Average Exercise Price, Exercised \| $ / shares		4.00		$ 4.05
Weighted Average Exercise Price, Expired \| (per share)	13.33	$ 4.00		$ 12.50
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 4.50		$ 9.04

Share Capital (Details 2) - $ / shares

12 Months Ended

Sep. 30, 2016

Sep. 30, 2015

Sep. 30, 2014

Class of Warrant or Right [Line Items]

Exercise Price

$ 4.50

$ 9.04

$ 9.05

Number of Warrants

1,265,626

1,022,761

1,054,531

Warrant One [Member]

Class of Warrant or Right [Line Items]

Exercise Price

$ 4.50

Number of Warrants

1,265,626

Expiry Date

^[1]

Jan. 06, 2022

[1]	Exercisable beginning January 6, 2017.

Share Capital (Details 3) - Warrants Exercised [Member]	1 Months Ended	12 Months Ended
Share Capital (Details 3) - Warrants Exercised [Member]	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Class of Warrant or Right [Line Items]
Risk free interest rate	1.12%	0.48%	0.44%	1.07%
Expected life (years)	11 days	14 days	4 months 24 days	3 months 7 days
Expected share price volatility	97.00%	92.00%	92.00%	106.00%

Share Capital (Details 4) - Warrants Granted [Member]	12 Months Ended
Share Capital (Details 4) - Warrants Granted [Member]	Sep. 30, 2016	Aug. 31, 2014
Class of Warrant or Right [Line Items]
Risk free interest rate	0.52%	1.48%
Expected life (years)	4 days	3 years
Expected share price volatility	91.00%	112.00%
Expected dividend yield	0.00%	0.00%

Share Capital (Details 5)	12 Months Ended
Share Capital (Details 5)	Sep. 30, 2016 $ / shares shares	Sep. 30, 2016 $ / shares shares	Sep. 30, 2015 $ / shares shares	Sep. 30, 2015 $ / shares shares
Class of Stock [Line Items]
Number of units, Beginning Balance \| shares	46,600	46,600	46,720	46,720
Number of units, Exercised \| shares	(40,000)	(40,000)	(120)	(120)
Number of units, Expired \| shares	(6,600)	(6,600)
Number of units, Ending Balance \| shares	0	0	46,600	46,600
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 1.87		$ 2.25
Weighted Average Exercise Price, Exercised \| $ / shares		$ 2.50		$ 5.00
Weighted Average Exercise Price, Expired \| $ / shares		$ 2.50
Weighted average exercise price, Ending Balance \| $ / shares	$ 0		$ 1.87

Share Capital (Details 6)	12 Months Ended
Share Capital (Details 6)	Sep. 30, 2016 $ / shares shares	Sep. 30, 2016 $ / shares shares	Sep. 30, 2015 $ / shares shares	Sep. 30, 2015 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Ending Balance	539,103	539,103
2013 Fixed Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Beginning Balance	557,638	557,638	588,553	588,553
Number of Options, Granted	56,300	56,300	16,500	16,500
Number of Options, Exercised			(38,750)	(38,750)
Number of Options, Expired	(21,334)	(21,334)	(3,333)	(3,333)
Number of Options, Expired	(53,501)	(53,501)	(5,332)	(5,332)
Number of Options, Ending Balance	539,103	539,103	557,638	557,638
Weighted Average Exercise Price, Beginning Balance \| $ / shares	$ 5.17		$ 5.56
Weighted Average Exercise Price, Granted \| (per share)	6.47			$ 13.30
Weighted Average Exercise Price, Exercised \| $ / shares				3.06
Weighted Average Exercise Price, Expired \| (per share)	10.70	$ 5.22	18.30	$ 7.76
Weighted Average Exercise Price, Ending Balance \| $ / shares	$ 5.29		$ 5.17

Share Capital (Details 7) - 12 months ended Sep. 30, 2016	$ / shares shares	$ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	539,103	539,103
Exercisable at Sep 30, 2016	514,570	514,570
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	283,610	283,610
Exercisable at Sep 30, 2016	283,610	283,610
Exercise Price Range, Lower Range Limit \| $ / shares		$ 0.01
Exercise Price Range, Upper Range Limit \| $ / shares		$ 5.00
Expiry Date, Start	2017-04	2017-04
Expiry Date, End	2019-12	2019-12
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	8,600	8,600
Exercisable at Sep 30, 2016	2,867	2,867
Exercise Price Range, Lower Range Limit \| $ / shares	$ 0.01
Exercise Price Range, Upper Range Limit \| $ / shares	$ 5.00
Expiry Date, End	2023-09	2023-09
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	142,860	142,860
Exercisable at Sep 30, 2016	141,193	141,193
Exercise Price Range, Lower Range Limit \| $ / shares		$ 5.01
Exercise Price Range, Upper Range Limit \| $ / shares		$ 10.00
Expiry Date, Start	2017-10	2017-10
Expiry Date, End	2022-06	2022-06
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	33,033	33,033
Exercisable at Sep 30, 2016	15,900	15,900
Exercise Price Range, Lower Range Limit \| $ / shares	$ 5.01
Exercise Price Range, Upper Range Limit \| $ / shares	$ 10.00
Expiry Date, End	2022-12	2022-12
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	21,500	21,500
Exercisable at Sep 30, 2016	21,500	21,500
Exercise Price Range, Lower Range Limit \| $ / shares		$ 15.01
Exercise Price Range, Upper Range Limit \| $ / shares		$ 20.00
Expiry Date, Start	2018-11	2018-11
Expiry Date, End	2021-11	2021-11

Share Capital (Details 8) - Employee Stock Option [Member]	12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.01%	1.65%	2.01%
Expected life (years)	7 years	7 years	6 years 9 months
Expected share price volatility	117.00%	115.00%	120.00%
Expected dividend yield	0.00%	0.00%	0.00%

Share Capital (Details Textual)	1 Months Ended	12 Months Ended
Share Capital (Details Textual)	Sep. 30, 2014 USD ($) $ / shares	Sep. 30, 2016 USD ($) $ / shares shares	Sep. 30, 2015 USD ($) $ / shares	Aug. 31, 2014 USD ($) $ / shares	Aug. 31, 2013 $ / shares shares	Aug. 31, 2012 shares
Share Capital [Line Items]
Warrants, exercise price \| $ / shares	$ 9.05	$ 4.50	$ 9.04
Weighted average contractual life remaining on the outstanding options		2 years 6 months 25 days
Weighted average fair value of share options awarded \| $ / shares		$ 5.56	$ 9.48	$ 15.14
Unrecognized share-based compensation expense \| $		$ 86,000
Unrecognized share-based compensation expense, recognition period		1 year 6 months
Intrinsic value of the options exercised \| $	$ 15.99		$ 8.28	$ 12.78
Intrinsic value of the vested options \| $		$ 0.10
Warrant [Member]
Share Capital [Line Items]
Weighted average contractual life remaining on the outstanding warrants		63 months
Common Shares [Member]
Share Capital [Line Items]
Shares issued to acquire license (in shares)					37,120
Warrants, exercise price \| $ / shares					$ 12.50
Common shares to be called by warrants					27,840
Common shares to be called by each warrant					1
Performance Shares [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance						1,000,000
Share based compensation, shares outstanding		383,838
Employee Share Option [Member]
Share Capital [Line Items]
Share based compensation, shares reserved for issuance		1,000,000
Share based compensation, share option vesting schedule		Share options granted to directors, officers, employees and consultants are subject to the following vesting schedule: (a)One-third shall vest immediately; (b) One-third shall vest 12 months from the date of grant; and (c) One-third shall vest 18 months from the date of grant.Share options granted to investor relations consultants vest over a period of not less than 12 months as to 25% on the date that is three months from the date of grant, and a further 25% on each successive date that is three months from the date of the prior vesting.

Income Taxes (Details) - USD ($)	1 Months Ended	12 Months Ended
Income Taxes (Details) - USD ($)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Income Tax Contingency [Line Items]
U.S.	$ (334,841)	$ (4,001,206)	$ (3,258,355)	$ (4,183,392)
Canadian	1,462,652	(1,026,520)	405,203	(4,096,931)
Other foreign	3,893	8,846	46,923	(132,000)
Income (Loss) Before Income Tax	$ 1,131,704	$ (5,018,880)	$ (2,806,229)	$ (8,412,323)

Income Taxes (Details 1) - USD ($)	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2014	Aug. 31, 2014
Deferred income tax assets:
Non-capital loss carry-forwards	$ 10,000,000	$ 8,028,900	$ 6,561,000	$ 6,418,300
Research and development tax credits	808,000	716,400	626,900	616,600
Deferred expenses	70,000	82,900	84,000	90,000
Property, plant and equipment	400	1,700	0	0
Share issuance costs	207,200	67,800	124,700	131,800
Deferred income tax liabilities:
U.S. federal benefit net of state taxes	(764,500)	(628,800)	(517,100)	(509,000)
Property, plant and equipment	0	0	(13,600)	(14,500)
Valuation allowance	(10,321,100)	(8,268,900)	(6,865,900)	(6,733,200)
Net deferred income tax asset (liability)	$ 0	$ 0	$ 0	$ 0

Income Taxes (Details 2) - USD ($)	1 Months Ended	12 Months Ended
Income Taxes (Details 2) - USD ($)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Income Tax Contingency [Line Items]
Combined Canadian federal and provincial tax rates	26.00%	26.00%	26.00%	26.00%
Expected income tax (recovery)/expense	$ 294,300	$ (1,304,900)	$ (729,600)	$ (2,187,200)
Nondeductible share-based payments	9,500	(67,400)	69,500	248,700
Nondeductible change in fair value of warrant liability	(436,800)	(55,100)	(554,100)	659,300
Effect of higher income tax rate in U.S.	(46,000)	(550,600)	(445,800)	(602,100)
Foreign currency differences	25,400	20,000	169,900	(50,900)
Other	(3,800)	(2,800)	(43,300)	(219,800)
Change in valuation allowance on deferred tax assets	161,200	1,968,000	1,570,200	2,179,200
Income tax expense	$ 3,800	$ 7,200	$ 36,800	$ 27,200

Income Taxes (Details 3) - USD ($)	1 Months Ended	12 Months Ended
Income Taxes (Details 3) - USD ($)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Current tax provision
U.S. federal	$ 0	$ 0	$ 0	$ 0
Canadian	0	0	0	0
Other foreign	3,000	6,400	36,000	26,400
State	800	800	800	800
Deferred tax provision
U.S. federal	(107,100)	(1,265,700)	(1,032,200)	(1,431,400)
Canadian	(21,600)	(303,300)	(209,300)	(289,800)
State	(32,500)	(399,000)	(328,700)	(458,000)
Change in valuation allowance on deferred tax assets	161,200	1,968,000	1,570,200	2,179,200
Income tax expense	$ 3,800	$ 7,200	$ 36,800	$ 27,200

Income Taxes (Details Textual) - 12 months ended Sep. 30, 2016	USD ($)	CAD ($)
Federal [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 20,708,000
Federal [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Federal [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036
Federal [Member] \| Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 384,000
Federal [Member] \| Research Tax Credit Carryforward [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2030
Federal [Member] \| Research Tax Credit Carryforward [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036
California [Member]
Income Tax [Line Items]
Operating Loss Carryforwards	$ 20,472,000
California [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2018
California [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036
California [Member] \| Research Tax Credit Carryforward [Member]
Income Tax [Line Items]
Tax Credit Carryforward, Amount	$ 424,000
Canadian [Member]
Income Tax [Line Items]
Operating Loss Carryforwards		$ 5,855,000
Canadian [Member] \| Earliest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2029
Canadian [Member] \| Latest Tax Year [Member]
Income Tax [Line Items]
Operating Loss Carryforwards, Expiration Date	Dec. 31, 2036

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Details) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Noncash or Part Noncash Acquisitions [Line Items]
Cash paid during the period for taxes	$ 800	$ 7,200	$ 36,800	$ 30,200

Supplemental Disclosure of Cash Flow and Non-Cash Transactions (Details 1) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Noncash or Part Noncash Acquisitions [Line Items]
Share issuance costs - broker units and warrants	$ 0	$ 0	$ 0	$ 386,898
Share issuance costs withheld from escrow proceeds	0	472,500	0	386,325
Transfer to common shares on exercise of warrants	890,214	1,853,581	10,000	6,591,546
Transfer to common shares on exercise of options	13,533	0	113,561	489,136
Transfer to common shares on issuance of performance shares	0	0	0	422,728
Shares subscribed transferred to common shares	$ 0	$ 0	$ 0	$ 5,155,674

Fair Value of Financial Instruments (Details) - USD ($)	Sep. 30, 2016	Sep. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	$ 3,988,794
Short-term investments in mutual fund debt securities		$ 5,015,171
Warrant liability, current portion	0	1,550,630
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	3,988,794
Short-term investments in mutual fund debt securities		5,015,171
Warrant liability, current portion		0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	0
Short-term investments in mutual fund debt securities		0
Warrant liability, current portion		1,550,630
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments in U.S. Treasury Bills	$ 0
Short-term investments in mutual fund debt securities		0
Warrant liability, current portion		$ 0

- Definition

Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Trading Securities
-URI http://asc.fasb.org/extlink&oid=6526789

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 35
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=27723805&loc=d3e24584-111560

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65884222&loc=d3e22054-111558

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Available-for-Sale Securities
-URI http://asc.fasb.org/extlink&oid=6505594

+ Details

Concentrations of Credit Risk (Details)	1 Months Ended	12 Months Ended
Concentrations of Credit Risk (Details)	Sep. 30, 2014	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2014
Customer Concentration Risk [Member] \| Product sales and contract services revenue [Member] \| Three Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage	86.00%	76.00%	82.00%
Customer Concentration Risk [Member] \| Product sales and contract services revenue [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage				73.00%
Customer Concentration Risk [Member] \| Grant revenue [Member] \| One Grantor [Member]
Concentration Risk [Line Items]
Concentration risk percentage				100.00%
Customer Concentration Risk [Member] \| Accounts receivable [Member] \| Two Customers [Member]
Concentration Risk [Line Items]
Concentration risk percentage			91.00%
Customer Concentration Risk [Member] \| Accounts receivable [Member] \| One Customer [Member]
Concentration Risk [Line Items]
Concentration risk percentage		100.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Europe [Member]
Concentration Risk [Line Items]
Concentration risk percentage	9.00%	43.00%	53.00%	41.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Asia [Member]
Concentration Risk [Line Items]
Concentration risk percentage	28.00%	45.00%	38.00%	40.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| U.S. [Member]
Concentration Risk [Line Items]
Concentration risk percentage	62.00%	12.00%	9.00%	14.00%
Geographic Concentration Risk [Member] \| Revenue [Member] \| Other countries [Member]
Concentration Risk [Line Items]
Concentration risk percentage	0.00%	0.00%	0.00%	6.00%